HDAC Inhibitors Market

HDAC Inhibitors Market Overview

The global HDAC inhibitors market is estimated to grow from USD 1.2 billion in 2024 to reach USD 1.3 billion in 2025 and USD 2.8 billion by 2035, representing a higher CAGR of 7.8% during the forecast period. Epigenetics is defined as a heritable change in the gene expression and its activity without alteration in the DNA sequence. The different epigenetic mechanisms through which gene expression can be modulated primarily include histone modification, DNA methylation, alteration of chromatin architecture and involvement of small-interfering or non-coding RNAs. Enzymes such as histone acetyltransferases (HATs), histone methyltransferases (HMTs), histone deacetylases (HDACs) and histone demethylases (DMTs) play significant role in epigenetic regulation. HATs and HDACs are the two major enzyme classes involved in post-translational modification of N-terminal tail of the histone proteins; HATs are responsible for acetylation of N-terminal histone tail whereas HDACs possess an opposite mode of action and act by removing the attached acetyl group.

Currently, HDACs are widely being studied as a promising therapeutic target. HDAC inhibitors can be classified into four main categories based on the structural characteristics of the Zn²⁺ binding domain. These include hydroxamic acids, cyclic peptides, short-chain fatty acids and benzamides. In addition to the synthetic HDAC inhibitors, the HDAC inhibitory role of various naturally occurring molecules has recently been discovered. These include molecules such as curcumin, depudecin, flavone and taipoxin.

There are five commercialized HDAC inhibitors, majority of which are primarily targeting hematological malignancies. Approval of the first HDAC inhibitor, Zolinza™(vorinostat), in 2006 for treatment of CTCL gave the market an initial impetus. The momentum was carried on by the other molecules that were marketed in 2009 (Istodax®), 2014 (Beleodaq®, Epidaza®) and 2015 (Farydak®). These drugs are currently being evaluated for several other indications as a single agent or as a combination therapy in lower stages of development.

Recent Developments in HDAC Inhibitors Market:

Several recent developments have taken place in HDAC inhibitors market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In September 2023, Shuttle Pharma announced the expansion of patent coverage on HDAC inhibitor platform. 
• In June 2023, Italfarmaco Group announced Food and Drug Administration (FDA) completion for Givinostat. Givinostat is the company’s proprietary histone deacetylase inhibitors for the treatment of Duchenne Muscular Dystrophy (DMD).

Scope of the Report

The “HDAC Inhibitors Market: Industry Trends and Forecasts, till 2035” report was commissioned to examine the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the HDAC inhibitors market. HDACs have been studied in cellular processes such as apoptosis, autophagy, metabolism, DNA damage response repair, cell cycle control and senescence. Altered expression of HDACs has been observed in different tumors; this makes them a potential target for treatment of cancer and other genetic or epigenetic related disorders. Inhibition of HDACs has shown positive results in disruption of multiple cell signaling pathways and prevention of tumor growth.

The HDAC inhibitors market has steadily evolved over the last few years with many drug candidates designed to address a wide range of oncological and non-oncological disorders. With five commercialized products, the market has gained attention from several industry and non-industry players. Initially, the market was led by big pharma players; however, the success of the marketed products has encouraged several start-ups and mid-sized firms to step into this lucrative space. We identified around 21 start-ups and 14 mid-sized companies that are exploring the opportunities presented by HDAC inhibitors. Currently, the HDAC inhibitors’ pipeline comprises of over 90 molecules under development. It is worth highlighting that over the last few years, the focus has shifted from pan-HDAC to class-specific HDAC inhibitors. Additionally, the research activity, with respect to the number of publications, has been highly promising. With an intense research framework, there have been over 9500 papers published in the last 10 years (as captured in PubMed). Further, increasing popularity on social media validates the growing interest in HDAC inhibitors market. The analysis conducted till 2035, demonstrates a Compound Annual Growth Rate (CAGR) of 7.8% in the overall market.

As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this market report was to understand the future potential of HDAC inhibitors market. This was done by analyzing:

• The HDAC inhibitor pipeline (marketed, clinical and preclinical drugs) in terms of phase of development, HDAC class specificity and the evolving therapeutic areas / target indications.
• The likely adoption of the HDAC inhibitors by understanding the competition posed by the current treatment regime in the coming few years.
• The emerging trends and the popularity of HDAC inhibitors on social media such as Twitter and Facebook over the last few years.
• The research activity in this field in terms of the focus of the publications / research articles granted across the globe in the last two years.

The key objective of HDAC inhibitors market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for HDAC inhibitors market during the forecast period. The research, analysis and insights presented in this market report include potential sales of the approved drugs and the ones in late stages of development (phase III and phase II). To add robustness to our model, we have provided three scenarios for our market forecast; these include the conservative, base and optimistic scenarios. Our opinions and insights, presented in this market research report were influenced by several discussions we conducted with experts in this area. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.